Hologic reported a solid start to fiscal year 2026, with revenue slightly exceeding guidance and non-GAAP EPS at the high end of expectations. The company's Breast Health and Molecular Diagnostics segments showed strong growth, offsetting a decline in Diagnostics revenue. Management expressed confidence in achieving full-year guidance.
Total revenue for the first quarter of fiscal 2026 was $1.025 billion, a slight increase from the previous year.
Non-GAAP diluted EPS reached $1.05, at the high end of the company's guidance range.
Breast Health revenue grew by 4.5% to $350.0 million, driven by strong demand for breast imaging and interventional solutions.
Diagnostics revenue decreased by 1.5% to $500.0 million, primarily due to lower COVID-19 related sales.
Hologic reaffirmed its full-year fiscal 2026 revenue guidance of $4.00 billion to $4.10 billion and non-GAAP diluted EPS guidance of $4.00 to $4.15, reflecting confidence in continued growth across key segments.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance